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ABSTRACT 
Heart transplant recipients are at an increased risk for cerebral hemorrhage and 
ischemic stroke, yet the exact mechanism for this derangement remains unclear. We 
hypothesized that alterations in cerebrovascular regulation is principally involved. To test 
this hypothesis, we studied cerebral pressure-flow dynamics in 8 clinically stable male 
heart transplant recipients (62 ± 8 years of age and 9 ± 7 years post-transplant, mean + 
SD), 9 male age-matched controls (63 ± 8 years) and 10 male donor controls (27 ± 5 
years).  To increase blood pressure variability and improve assessment of the pressure-
flow dynamics, subjects performed squat-stand maneuvers at 0.05 and 0.10 Hz.  Beat-to-
beat blood pressure, middle cerebral artery velocity, and end-tidal carbon dioxide were 
continuously measured during five minutes of seated rest, and throughout the squat-stand 
maneuvers. Cardiac baroreceptor sensitivity gain and cerebral pressure-flow responses 
were assessed with linear transfer function analysis. Heart transplant recipients had 
reductions in R-R interval power and baroreceptor sensitivity low frequency gain 
(P<0.01) compared to both control groups; however, these changes were unrelated to 
transfer function metrics.  Thus, in contrast to our hypothesis, the increased risk of 
cerebrovascular complication after heart transplantation does not appear to be related to 
alterations in cerebral pressure-flow dynamics. Future research is therefore warranted. 
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INTRODUCTION 
The longevity of heart transplant recipients has increased from 18 days following 
the first heart transplantation surgery1 to a current mean survival expectancy of over 10.5 
years.2 The improved survival has lead to alterations in the long-term functional 
outcomes post transplantation.  For example, neurological impediments develop in 
approximately 60-80% of heart transplant recipients,3-5 and have a 14-18% greater 
occurrence rate of cerebral hemorrhage or ischemic stroke.3,5-7 The exact mechanism for 
these derangements however remains to be elucidated; however, adverse events may be 
the direct consequence of life-long immunosuppressant therapy,8 or vascular remodeling 
secondary to chronic cerebral hypoperfusion associated with pre-transplant heart 
failure.4,5,7  
We asked whether alterations in cerebral pressure-flow dynamics could also 
explain the increased risk. Indeed, because of cardiac allograft, there are marked 
reductions in heart rate variability9,10 and baroreceptor sensitivity (BRS),9 which could 
lead to unstable control of blood pressure in this clinical population. Evidence indicates 
that the responses of the cerebral vessels in some animals11 and humans12 are likely 
influenced by a coordinated reaction of the cardiovascular system as a whole especially 
when there are disturbances to the blood or oxygen supply to the brain.13 Moreover, both 
animal14,15 and human12 studies have demonstrated the inverse relationship between 
cardiac BRS and dynamic cerebral autoregulation. In other words, at least in healthy 
young humans, dynamic cerebral autoregulation may compensate for reductions in 
cardiac BRS and vise-versa. These concepts have not been explored in a clinical model 
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(e.g., the heart transplant recipient) where cardiac baroreceptor function is markedly 
reduced or abolished. Thus, research is warranted in the long-term heart transplant 
recipient population to determine the impact of marked reductions in cardiac autonomic 
control on cerebral blood flow regulation. 
Accordingly, we examined the dynamic relationship between beat-to-beat 
changes in blood pressure and cerebral blood flow in long-term heart transplant recipients 
under spontaneous conditions, as well as during frequency dependent squat-stand 
maneuvers. To control for the influence of heart transplantation per se, we compared 
patients with age-matched controls. To control for the influence of age, heart transplant 
recipients were also compared to a group of donor-controls. We hypothesized that heart 
transplant recipients would have reduced BRS, and impaired cerebral pressure-flow 
dynamics, independent of age.   
 
METHODS 
Ethical approval 
 The study was approved by the clinical ethical committees of the Universities of 
British Columbia and Alberta, and adhered to the principles of the Declaration of 
Helinski.  All volunteers provided written informed consent.  
Participants 
Eight male clinically stable heart transplant recipients (62 ± 8 years of age, 9 ± 7 
years post-transplant), 9 male age-matched controls (63 ± 8 years) and 10 male donor 
controls (27 ± 5 years), were recruited for this study (Table 1). Seven of the eight heart 
transplant recipients were ischemic pre-surgery etiology.  All subjects were extensively 
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screened by the attending cardiologist for any clinical history of respiratory, 
cardiovascular or cerebrovascular diseases. Resting and exercise echocardiograms were 
performed by a cardiologist on all participants. In additional, we screened (via an 
transcranial Doppler examination) the anterior intra-cranial vessels for any signs intra-
cranial stenosis; all subjects had normal examination results as indicated by normal intra-
cranial velocity profiles.16 All subjects were carefully screened for activity levels, 
withdrew from caffeine and alcoholic beverages for a period of 12 hours prior to the 
study and all medications were maintained for the study. Each subject underwent a 
familiarization of the laboratory and testing protocols.  
Instrumentation 
 Three-lead electrocardiogram (ECG) was employed for the measurement of the 
R-R interval and heart rate.  Blood pressure was measured in the finger by 
photoplethysmography (Finometer; Finapres Medical Systems, Amsterdam, The 
Netherlands).  This method has been shown to reliably assess the dynamic changes in 
beat-to-beat blood pressure that correlate well with the intra-arterial recordings and can 
be used to quantify the dynamic pressure-flow relationship of cerebral circulation.17 
Intermittent blood pressure was also recorded in the arm by electrosphygmomanometry 
(SunTech Medical, Morrisville, NC, USA), with a microphone placed over the brachial 
artery and the Korotkoff sounds gated to the ECG.  Throughout the experiment, the 
validity of the finger blood pressure recordings were intermittently confirmed at the 
brachial artery in the contralateral arm by sphygmomanometry.   
Both right and left middle cerebral arteries (MCA) were insonated by placing a 2-
MHz Doppler probe (Spencer Technologies, Seattle, WA, USA) to obtain bilateral 
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cerebral blood velocity.  The MCA were identified according to their signal depth, wave 
form and velocities.16 Once the MCA were identified the probes were secured and locked 
in place with a head-band (Spencer Technologies, Seattle, WA, USA).  An index of 
cerebrovascular resistance (CVRi) was calculated from mean arterial pressure (MAP)/ 
mean MCA velocity (MCAv).  
End-tidal CO2 (PETCO2) was measured using an online gas analyser (ML206; AD 
Instruments, Colorado Springs, CO, USA), calibrated with a known gas concentration 
prior to each subject.  All data were recorded and stored for subsequent analysis using 
commercially available software (LabChart version 7.1; AD Instruments, Colorado 
Springs, CO, USA).  
Procedure 
 At least 5 minutes of resting spontaneous baseline data were recorded in the 
seated position.  These data were used for spectral analysis of spontaneous oscillations in 
blood pressure and cerebral blood flow velocity.  Next the subjects performed repeated 
squat-stand maneuvers. The subjects mimicked the experimenter in performing these 
maneuvers.  In random order, subjects then performed squat-stand maneuvers at 0.05 Hz 
(10 second squat–10 second stand) and then 0.10 Hz (5 second squat–5 second stand) for 
5 minutes, with a 5-minute rest period to return to baseline levels in between trials.  
These data were used for the spectral analysis of the driven oscillations in blood pressure 
and MCAv and were performed to increase the blood pressure variability, resulting in 
increased coherence (allowing for a more robust mathematical assessment of the phase 
and gain metrics).18 End tidal gases were monitored to ensure that normal breathing 
occurred and Valsalva-like maneuvers were avoided. 
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Data Processing 
All data were simultaneously sampled at 1000 Hz via an analog-to-digital 
converter (Powerlab 16/30 ML880; AD Instruments, Colorado Springs, CO, USA).  Real 
time beat-to-beat mean values of blood pressure and MCA velocity were determined 
from each R-R interval. All data were processed and analyzed with custom designed 
software in LabView 10 (National Instruments, Texas, USA). 
 
Power spectrum and transfer function analysis 
Beat-to-beat MAP and MCAv signals were spline interpolated and re-sampled at 
4-Hz for spectral and transfer function analyses based on the Welch algorithm.  Each 5-
minute recording was first subdivided into 5 successive windows that overlapped by 
50%. Data within each window were linearly detrended and passed through a Hanning 
window prior to fast Fourier transform analysis. For transfer function analysis, the cross-
spectrum between MAP and MCAv was determined and divided by the MAP auto-
spectrum to derive the transfer function coherence, gain, and phase.   
Spontaneous MAP and MCAv power spectrum density (PSD), and the mean 
value of transfer function coherence, normalized gain and phase were calculated in the 
very low (VLF, 0.02-0.07 Hz) and low (LF, 0.07-0.20 Hz), frequency ranges as 
previously defined.19 The transfer function coherence, gain and phase of the driven blood 
pressure oscillations were sampled at the driven frequency (0.05 or 0.10 Hz).  Gain was 
normalized as % MCAv / absolute blood pressure, as MCAv varied between groups but 
blood pressure was not significantly different. The absolute gain values were not reported 
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in this study as the MCA diameter were not measured nor were repeated measures 
performed, thus making absolute gain comparisons across individuals unreliable. 
Individual phase and gain estimates were entered for subsequent analysis only where the 
corresponding coherence between blood pressure and MCA velocitymean was >0.5 
indicating at least 50% shared variance.   
 
R-R Interval and Cardiac Baroreceptor Sensitivity Gain 
From the ECG and blood pressure waveform, we determined the time of each R 
wave, and beat-to-beat values of systolic blood pressure. The cardiac period (R-R 
interval) time series was checked for the presence of artifacts, and spuriously detected or 
missed R waves were corrected by linear interpolation. Power spectral analysis was 
performed on the R-R interval and systolic blood pressure. Both the R-R interval and 
beat-to-beat systolic blood pressure were high pass filtered to remove fluctuations of 
<0.015 Hz, low pass filtered to exclude components of >2 Hz (Nyquist frequency), and 
re-sampled at 4 Hz. These series were then passed through a Hanning window and 
subject to fast Fourier transform analysis. Spontaneous LF gain was assessed in the range 
of 0.04-0.15 Hz and driven BRS gain was assessed from the 0.10 Hz squat-stand 
maneuvers.  This method has been previously validated against the modified Oxford 
method.20 
Critical Closing Pressure and Pulsitility Index Calculations 
Critical closing pressure was calculated by the linear extrapolation of the cerebral 
blood flow velocity and blood pressure relationship below the diastolic values to the 
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zero-flow pressure.21 Pulsitility index was calculated as: (systolic MCAv – diastolic 
MCAv) / mean MCAv. 
Statistical Analysis 
 Statistical analyses were performed using SPSS version 20.0. The effects of 
condition (spontaneous resting, 0.05 Hz, 0.10 Hz) or Group (heart transplant recipients, 
age-matched, donor-controls) on cerebral blood flow velocity, Heart Rate, blood pressure 
(mean and systolic), PETCO2, CVRi, critical closing pressure, pulsitility index and 
transfer function coherence, normalized gain and phase were assessed using a one-way 
ANOVA with a post hoc Tukey comparison for group effects. Bivariate correlations 
between BRS gain and transfer function coherence, normalized gain and phase were 
performed using Pearson Product Moment.  Data are presented as mean ± SD. 
 
RESULTS 
 
Demographics (Table 1 and 2) 
 There were no significant differences between groups for BMI (Table 1).  By 
study design, donor-controls were significantly younger than heart transplant recipients 
and age-matched controls.  During the seated baseline testing and both driven frequencies 
(0.05 Hz and 0.10 Hz) mean arterial pressure, systolic blood pressure, pulse pressure and 
PETCO2 levels were comparable for all groups (Table 2).  Critical closing pressures for all 
subjects were physiologically relevant values (all positive) and were comparable between 
all groups. Resting heart rate was reduced in the age-matched controls (68 ± 13 bpm) and 
donor-controls (63 ± 8 bpm) compared to heart transplant recipients (91 ± 8 bpm).   
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MCAv was reduced in both older populations (heart transplant recipients 41 ± 8; age-
matched 42 ± 8 cm/s) compared to donor-controls (62 ± 7 cm/s).  Puslitility index 
(arbitrary units) at rest was reduced in the heart transplant recipients (0.83 ± 0.12) 
compared to both the age-matched (1.01 ± 0.17) and donor (1.02 ± 0.11) controls.  
During the driven protocols, heart rate was similarly elevated in the heart transplant 
recipients compared to age-matched and donor-controls and the MCAv was reduced in 
compared to the donor-controls, pulsitility index was comparable for all groups (Table 2). 
The older populations (2.2-2.3 mmHg/cm/s) had an elevated CVRi compared to the 
younger group (1.4-1.5 mmHg/cm/s) across all testing protocols.  
Representative data tracing – that was similar between groups – of blood pressure, 
MCAv and PETCO2 for the seated baseline, 0.05 Hz and 0.10 Hz squat-stand manoeuvres 
from a heart transplant recipient are shown in Figure 1.  As shown in Figure 1, the squat-
stand maneuvers evoked clear oscillations in both blood pressure and MCAv, whereas 
PETCO2 levels were well maintained in all groups (Table 2).  
 
Cardiac Baroreceptor Sensitivity (Table 3) 
 The donor-controls had a significantly higher spontaneous BRS LF gain (10.8 ± 
5.1 ms/mmHg) compared to both the heart transplant recipients (1.4 ± 1.2 ms/mmHg; 
p<0.01) and the age-matched controls (4.4 ± 1.8 ms/mmHg; p<0.01).  The heart 
transplant recipients also had a significantly reduced BRS LF gain as compared to the 
age-matched controls (Table 3).  During the 0.10 Hz squat-stand manoeuvres, all groups 
were significantly different (heart transplant recipients 0.2 ± 0.1 ms/mmHg; age-matched 
2.0 ± 0.9 ms/mmHg; donor-controls 3.9 ± 1.0 ms/mmHg; p<0.03, Table 3). The donor-
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controls showed a marked elevation in their R-R interval PSD when compared with both 
the heart transplant recipients (p<0.01) and age-matched controls (p<0.05) in the 
spontaneous and driven LF ranges (Table 3).  The R-R interval PSD for the age-matched 
controls was also elevated when compared with the heart transplant recipients (Table 3).   
 
Cerebral Pressure-Flow Dynamics (Table 4) 
There were no differences between the groups (heart transplant recipients, age-
matched and donor-controls) when comparing the power spectrums for MAP or MCAv in 
either the VLF or LF ranges, during spontaneous and driven conditions (Table 4). The 
MAP and MCAv PSD was significantly increased during the squat-stand manoeuvres for 
all groups.   
Transfer function analysis phase and normalized gain was not significantly 
different between groups at either the 0.05 Hz or 0.10 Hz squat-stand frequencies (Figure 
3). There was also no relationship to the increased CVRi in the heart transplant recipients 
and age-matched as compared to the donor-controls and any transfer functional analysis 
metrics (Table 4). The reductions in BRS in both the heart transplant recipients and age-
matched controls under conditions of spontaneous rest, as well as both driven frequencies 
were unrelated to variability in the transfer function metrics.  
 
DISCUSSION 
 To our knowledge, this is the first study to assess cerebral pressure-flow 
relationship in long-term heart transplant recipients. Our findings show that despite 
marked reductions in cardiac BRS in heart transplant recipients, cerebral pressure-flow 
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dynamics remain intact. Moreover, reductions in BRS were not correlated to inter-
individual variability in transfer function analysis metrics in the heart transplant 
recipients.  
 
Cardiac Baroreceptor Sensitivity in Heart Transplant Recipients 
Following heart transplantation, the sympathetic and parasympathetic nerves that 
normally regulate heart rate are severed, leaving the heart denervated.  Our findings are 
consistent with prior studies showing reduced cardiac BRS in short-term (< 24 months) 
heart transplant recipients.22,23 In the longer-term (mean 5 years) heart transplant 
recipients, there is some evidence that partial sympathetic re-innervation may occur,10 as 
reflected in an increase in the R-R interval power spectrum at 0.10 Hz.  In this study, we 
observed a marked reduction in R-R interval power in the heart transplant recipients 
(reduced by >95% as compared to age-matched and >99% compared with donor-
controls; Table 3), which was positively correlated with BRS gain under both 
spontaneous (R2 = 0.38, p<0.01) and driven (R2 = 0.60, p<0.01) conditions. There was 
also an increase in the R-R interval power spectrum at 0.10 Hz in the heart transplant 
recipients, indicating some re-innervation of the sympathetic nervous system.10,23  
 
Cerebral Pressure-Flow Dynamics 
 Although the long-term heart transplant recipients had marked reductions in R-R 
interval and BRS gain (Table 3), these alterations did not impact their cerebral pressure 
flow dynamics (Table 4; Figure 3). We show that long-term heart transplant recipients 
have comparable reductions in MCAv and increases in CVRi compared to their age-
 13 
matched counterparts (Table 2). Moreover, the increase in CVRi with age does not 
appear to influence the transfer function analysis phase or normalized gain metrics 
studied in the present investigation – findings consistent with reports that cerebral 
pressure-flow dynamics are unaltered by age, at least up to the age of 75 [reviewed in:24]. 
We now extend these findings to include long-term heart transplant recipients (Table 4; 
Figure 3).   
 That long-term heart transplant recipients have comparable cerebral-pressure flow 
dynamics compared to both age-matched and donor-controls is clinically significant. We 
interpret these results to indicate that despite possible cerebrovascular remodeling during 
pre-transplant antecedent heart failure4,5,7, and reductions in resting pulsitility index 
(Table 2) and  cardiac BRS (Table 3), the cerebrovasculature is able to adapt to acute and 
marked (i.e., 40-45 mmHg) changes in arterial blood pressure (Fig 1; Table 2).  
 
Relationship between cardiac baroreflex and transfer function metrics 
 The reduction in cardiac BRS in heart transplant recipients was not correlated 
with transfer function metrics during either spontaneous or driven conditions.  These 
findings are consistent with a recent study25 in healthy older adults, which showed that 
increases in BRS was not related to dynamic cerebral autoregulation metrics.  The 
findings of these studies in older adults and in heart transplant recipients, contrast with 
those in young healthy adults which demonstrated that there was an inverse relationship 
between BRS and markers of dynamic cerebral autoregulation.12 Thus, reductions in 
cardiac BRS in aging and heart transplantation seem to play a diminished role in the 
integrated regulation of CBF.  
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Limitations: 
Transcranial Doppler ultrasonography: 
 The main assumption of transcranial Doppler is that the velocity recorded in the 
MCA is directly representative to changes in cerebral blood flow.  Throughout situations 
where there are normal arterial blood gas levels and blood pressure ranges the majority of 
research provides evidence that transcranial Doppler provides a reliable index of cerebral 
blood flow [reviewed in:16].  
 
Transfer Function Analysis:  
Transfer function analysis applies a linear mathematical approach to interpret the 
relationship between the input blood pressure and the output cerebral blood flow. The 
work by Zhang et al.19 has suggested that the cerebral autoregulatory system may be: 
linear, non-linear, have multiple inputs, or merely be two unrelated phenomena.  Hence 
during this study we did not discuss cerebral autoregulation per se, but merely presented 
data regarding to the relationship that exists between blood pressure and cerebral blood 
flow. The coherence present within the analysis will affect the mathematical 
interpretability of the transfer function analysis (phase and gain)26. We employed the 
squat-stand maneuvers to non-pharmalogically increase blood pressure variability, 
enhancing the coherence (driven coherence was >0.98 a.u.) and allowing for more 
mathematically interpretable transfer function analysis and gain metrics.18 In addition, we 
view the driven blood pressure challenges to be a realistic representation of natural 
oscillations that can occur to blood pressure activities of daily living (e.g., postural 
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changes, coughing, exercise, etc.) and thus makes our data set physiologically relevant. 
This methodology induced oscillations that were 40-45 mmHg (Table 2). Nevertheless, 
although the maximum myogenic regulatory control mechanism may not have been 
challenged enough to truly assess the risk factor for a cerebral haemorrhage or ischemic 
stroke, this would seem unlikely giving the physiological realistic changes in blood 
pressure. 
 
Arteriosclerosis:  
 The long-term heart transplant recipient patients were not screened invasively in 
for arthrosclerosis in this study, as this is not a routine procedure for this population.  The 
heart transplant recipients were more than five years post-transplant and did not have 
accompanying risk factors such as hypertension under resting conditions. Although the 
subjects within the current study did not undergo MRI, the normal intra-cranial velocities 
and dynamic pressure-flow relationships would indicate an absence of global cerebral 
arthrosclerosis. However, we cannot rule out the possibility of localized and regional 
arthrosclerosis.    
 
Cross-Sectional Design:  
 As this study is drawing conclusions from a cross-section of the population it is 
not possible to make a causal inference in the relationship between BRS and cerebral 
blood flow regulation.  It would be nearly impossible to perform a longitudinal study 
where the same population was followed from young healthy adults to older adults and 
had a subset of this population undergo heart transplant surgery. We would also like to 
acknowledge that the heart transplant recipients within this study were otherwise very 
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healthy individuals and our findings may not relate to heart transplant recipients with 
greater co-morbidities. 
 
PERSPECTIVES 
To our knowledge, this is the first study to date that has assessed the cerebral 
pressure-flow relationship in long-term heart transplant recipients. We have revealed 1) 
that in spite of reductions to BRS, long-term heart transplant recipients have comparable 
cerebral-pressure flow dynamics compared to both age-matched and donor-controls; and 
2) the reductions in BRS in long-term heart transplant recipients were not related to any 
transfer function metrics. Together these data indicate that the cerebrovasculature in long-
term heart transplant recipients is able to normally regulate the cerebral pressure-flow 
dynamics, and is unlikely to explain the increased occurrence of severe cerebrovascular 
complications documented in the population.  
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NOVELTY AND SIGNIFICANCE 
1) This is the first study to have assessed the relationship between arterial blood 
pressure and cerebral blood flow in long-term heart transplant recipients 
2) We have revealed 1) that in spite of reductions to BRS, long-term heart 
transplant recipients have comparable cerebral-pressure flow dynamics 
compared to both age-matched and donor controls; and 2) the reductions in 
BRS in long-term heart transplant recipients were not related to any transfer 
function metrics. Together these data suggest that the cerebrovasculature in 
long-term heart transplant recipients is able to normally regulate the cerebral 
pressure-flow dynamics, and is unlikely to explain the increased occurrence of 
severe cerebrovascular complications documented in the population.  
FIGURE LEGENDS 
Figure 1.  Typical trace for blood pressure (BP), middle cerebral artery velocity (MCAv) 
and End Tidal CO2 (PETCO2) during spontaneous (top), 0.05 Hz (middle) and 
0.10 Hz (bottom) trials from a long-term heart transplant recipient. 
Figure 2. MCAv transfer function analysis of coherence, phase, and normalized gain in 
the very low frequency (VLF) and low frequency (LF) for the group means of 
the spontaneous data for the three group: AM: age-matched controls (solid), 
HTR: heart transplant recipients (long dash), DC: donor-controls (short dash).  
Figure 3. MCAv transfer function analysis of coherence, phase, and normalized gain at 
the driven frequencies of 0.05 Hz (left) and 0.10 Hz (right) for the three group: 
AM: age-matched controls (black), HTR: heart transplant recipients (light 
grey), DC: donor-controls (dark grey).   
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TABLES 
Table 1. Participant Characteristics  
 
 HTR (n=8) AM (n=9) DC (n=10) 
Age (years) 62 ± 8 63 ± 8      27 ± 5 *† 
Body Mass Index (kg/m2) 27 ± 4 26 ± 3 26 ± 5  
Years after transplantation  9 ± 7   
Medications    
Corticosteroid  2   
Antiproliferative agent  4   
Calcinerurin inhibitor  4   
mTOR inhibitor  4   
Ca2+ channel blocker (diltiazem)  5  2  
ACE inhibitor  4  1  
Diuretic  3  1  
Aspirin  6  2  
Lipid –lowering agent  4   
 
Values are means ± SD. Seven HTR subjects were ischemic pre-surgery etiology, one 
was non-ischemic etiology. Heart transplant recipient (HTR); age-matched (AM); donor 
control (DC); target of rapamycin (TOR); angiotensin-converting enzyme (ACE).  
Statistical significance was set at P < 0.05, *denotes significance from HTR, †denotes 
significance from AM. 
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Table 2. Hemodynamic and Cerebrovascular Responses During Squat-Stand Maneuvers 
 
 HTR AM DC 
Baseline (Sitting)    
MAP (mmHg)   97 ± 8   99 ± 12   93 ± 5 
Pulse Pressure (mmHg)   41 ± 16   55 ± 28   47 ± 17 
Mean MCAv (cm/s) 41 ± 8 42 ± 8       62 ± 7*† 
Pulsitility Index (a.u.)   0.83 ± 0.12   1.01 ± 0.17*   1.02 ± 0.11* 
CVRi (mmHg/cm/s)   2.3 ± 0.5  2.3 ± 0.5         1.4 ± 0.2*† 
CrCP (mmHg) 47 ± 19   46 ± 16   48 ± 17 
Heart Rate (bpm) 91 ± 8     68 ± 13*      63 ± 8* 
End Tidal CO2 (mmHg)  36 ± 7  36 ± 4    38 ± 2 
Squat Stand (0.05 Hz)    
MAP - Squat (mmHg) 122 ± 17   122 ± 15 111 ± 10 
MAP - Stand (mmHg) 78 ± 18   78 ± 15 78 ± 12 
Systolic BP – Squat (mmHg)   202 ± 38   193 ± 28   174 ± 19 
Systolic BP – Stand (mmHg)   141 ± 51   134 ± 30   132 ± 17 
Pulse Pressure - Squat (mmHg)   122 ± 33   107 ± 25   94 ± 15 
Pulse Pressure - Stand (mmHg)   94 ± 51   83 ± 26   80 ± 12 
Mean MCAv (cm/s) 43 ± 7 44 ± 8    62 ± 8*† 
Pulsitility Index - Squat (a.u.)   0.93 ± 0.20   0.81 ± 0.17   0.87 ± 0.14 
Pulsitility Index - Stand (a.u.)   1.56 ± 0.30   1.34 ± 0.35   1.53 ± 0.28 
CVRi (mmHg/cm/s)   2.3 ± 0.4  2.2 ± 0.5      1.5 ± 0.2*† 
Heart Rate (bpm) 105 ± 11    78 ± 14*  79 ± 8* 
End Tidal CO2 (mmHg)  37 ± 7 36 ± 3 40 ± 3 
Squat-Stand (0.10 Hz)    
MAP - Squat (mmHg) 123 ± 20   128 ± 12 115 ± 10 
MAP - Stand (mmHg) 78 ± 11   82 ± 10 75 ± 10 
Systolic BP – Squat (mmHg)   204 ± 34   202 ± 26   181 ± 16 
Systolic BP – Stand (mmHg)   150 ± 32   141 ± 20   132 ± 18 
Pulse Pressure - Squat (mmHg)   120 ± 26   111 ± 26   98 ± 13 
Pulse Pressure - Stand (mmHg)   107 ± 34   88 ± 19   84 ± 14 
Mean MCAv (cm/s) 43 ± 9 44 ± 7       62 ± 8*† 
Pulsitility Index - Squat (a.u.)   0.91 ± 0.21   0.81 ± 0.16   0.81 ± 0.13 
Pulsitility Index - Stand (a.u.)   1.63 ± 0.27   1.43 ± 0.37   1.62 ± 0.25 
CVRi (mmHg/cm/s)   2.3 ± 0.3  2.3 ± 0.5         1.5 ± 0.2*† 
Heart Rate (bpm) 106 ± 10     82 ± 14*     80 ± 8* 
End Tidal CO2 (mmHg)  37 ± 6 38 ± 4    40 ± 4 
 
Values are means ± SD. Heart transplant recipient (HTR); age-matched (AM); donor 
control (DC); mean arterial pressure (MAP); blood pressure (BP); arbitrary units (a.u.); 
mean middle cerebral artery velocity (MCAvmean); cerebrovascular resistance index 
(CVRi).  Statistical significance was set at P < 0.05, *denotes significance from HTR, 
†denotes significance from AM. 
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Table 3. Transfer function analysis for cardiac baroreceptor sensitivity. 
 
Values are means ± SD. Age-Match Control (AM); Baroreceptor Sensitivity (BRS); 
Donor-Control (DC); Heart Transplant Recipient (HTR); R-R Interval (RRI); middle 
cerebral artery velocity (MCAv); low frequency (LF; 0.04-0.15 Hz).  Statistical 
significance was set at P < 0.05, *denotes significance from HTR, †denotes significance 
from AM. 
 
 
 
  
 HTR AM DC 
Baseline (Sitting)    
LF RRI Power 
(ms2) 23 ± 15 726 ± 665* 2842 ± 2920*† 
BRS LF Gain 
(ms/mmHg) 1.4 ± 1.2 4.4 ± 1.8* 10.8 ± 5.1*† 
Squat-Stand (0.10 Hz)    
RRI Power 
(ms2)/Hz 1255 ± 1155 97773 ± 91881* 420052 ± 266339*† 
BRS Gain 
(ms/mmHg) 0.2 ± 0.1 2.0 ± 0.9* 3.9 ± 1.0*† 
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Table 4. Transfer function analysis between BP and MCAv. 
 
Values are means ± SD. Age-Match Control (AM); Donor-Control (DC); Heart 
Transplant Recipient (HTR); mean arterial pressure (MAP); arbitrary units (a.u.); middle 
cerebral artery velocity (MCAv); very low frequency (VLF; 0.02-0.07 Hz); low 
frequency (LF; 0.07-0.20 Hz).  Statistical significance was set at P < 0.05, *denotes 
significance from HTR, †denotes significance from AM. 
 HTR AM DC 
Baseline (Sitting)    
VLF MAP Power (mmHg2) 8.261 ± 5.118 8.813 ± 7.619 8.554 ± 4.589 
LF MAP Power (mmHg2) 6.754 ± 4.705 5.093 ± 5.418 5.942 ± 3.164 
VLF MCAv Power (cm/s)2 3.071 ± 2.060 3.283 ± 3.814 5.316 ± 3.265 
LF MCAv Power (cm/s)2 2.784 ± 2.537 3.448 ± 6.187 6.069 ± 4.376 
VLF Coherence (a.u.) 0.599 ± 0.240 0.661 ± 0.175 0.551 ± 0.155 
LF Coherence (a.u.) 0.791 ± 0.093 0.713 ± 0.155 0.829 ± 0.045 
VLF Phase (radians) 0.831 ± 0.420 0.883 ± 0.347 0.920 ± 0.432 
LF Phase (radians) 0.416 ± 0.189 0.473 ± 0.155 0.570 ± 0.171 
VLF Gain (%/mmHg)  1.110 ± 0.368  1.135 ± 0.344  1.242 ± 0.285 
LF Gain (%/mmHg) 1.501 ± 0.256  1.635 ± 0.450 1.625 ± 0.239 
Squat Stand (0.05 Hz)    
MAP Power (mmHg2)/Hz 35423 ± 16637 32695 ± 15483 18639 ± 13019 
MCAv Power (cm/s)2/Hz 6410 ± 3582 6525 ± 2950 8305 ± 4839 
Coherence (a.u.) 0.989 ± 0.010 0.984 ± 0.015 0.981 ± 0.013 
Phase (radians) 0.650 ± 0.194 0.494 ± 0.189 0.727 ± 0.209 
Gain (%/mmHg) 1.045 ± 0.321 1.025 ± 0.202 1.159 ± 0.208 
Squat-Stand (0.10 Hz)    
MAP Power (mmHg2)/Hz 21450 ± 7115 23389 ± 11799 14040 ± 7870 
MCAv Power (cm/s)2/Hz 6534 ± 3426 8893 ± 5863 11549 ± 5285 
Coherence (a.u.) 0.993 ± 0.009 0.989 ± 0.021 0.988 ± 0.014 
Phase (radians) 0.376 ± 0.102 0.310 ± 0.177 0.405 ± 0.119 
Gain (%/mmHg) 1.285 ± 0.236 1.342 ± 0.478 1.527 ± 0.245 
